NewMarket (NEU) Q4 2024 Earnings Call Transcript

NewMarket reported full-year 2024 net income of $462 million, or $48.22 per share, up from $389 million last year, while petroleum additives operating profit increased to $592 million from $514 million despite slightly lower sales. The AMPAC acquisition boosted Specialty Materials revenue to $141 million for the year and the company said results exceeded pre-acquisition expectations, though some profit was flattered by zero-margin inventory sales. Leverage improved to 1.2x net debt/EBITDA after $373 million of revolving credit repayments, and the company returned $128 million to shareholders through dividends and buybacks.

Analysis

NEU’s setup is less about headline earnings and more about the quality of those earnings: the core additives franchise is proving it can expand margin even in a flat-to-down volume backdrop, which usually signals pricing power mixed with real cost takeout rather than one-off cyclical tailwinds. That matters because this business tends to rerate when investors believe operating leverage is durable; the current combination of lower leverage, strong free cash flow, and capital returns raises the probability of a “defensive compounder” multiple expansion over the next 2-4 quarters.

The more interesting second-order effect is the specialty materials buildout. AMPAC gives NEU exposure to defense/space spend with a much longer demand runway than the additives segment, but the near-term optics are noisy because fair-value inventory accounting suppresses margin comparability. That creates a potential setup where reported growth may look mediocre for 1-2 quarters while the market underestimates the incremental earnings power once acquisition accounting rolls off and the backlog converts.

The main risk is that the market extrapolates cost savings too aggressively. If inflation re-accelerates in raw materials or freight, NEU’s margin gains could compress quickly because the company has already harvested a meaningful amount of easy efficiency. A second risk is valuation: with leverage already low and cash being returned, upside likely depends on sustained mid-single-digit earnings growth, not multiple support alone.

Consensus may be underappreciating the balance-sheet optionality. A 1.2x net debt-to-EBITDA profile gives management room to keep buying back stock or do tuck-in M&A, and in a market that rewards capital discipline, that can matter more than a few points of top-line growth. The stock looks better as a steady compounder than a momentum name; any weakness tied to near-term inventory normalization is more likely a buying opportunity than a thesis break, provided volumes stay stable and specialty materials ramps as expected.

Key Decisions for Investors

• Go long NEU on any 5-8% pullback over the next 1-3 months; risk/reward is attractive if the market is discounting near-term volume softness while ignoring margin durability and balance-sheet flexibility.
• Own NEU vs. a basket of industrials/chemicals via a relative-value pair (long NEU / short cyclical materials exposure) for 2-3 quarters; the hedge is that NEU’s cash conversion and capital return profile should hold up better in a slower macro tape.
• If options liquidity allows, buy 3-6 month call spreads on NEU to express a rerating toward higher-quality compounder multiples; cap downside while capturing potential multiple expansion as AMPAC uncertainty fades.
• Do not chase after earnings strength; wait for a catalyst entry when management provides evidence that Specialty Materials is exiting acquisition-accounting drag and converting into normalized operating margin.
• Use the improved leverage profile as a monitoring trigger: if buybacks accelerate without deterioration in operating profit, add on confirmation rather than speculation.